{"product_id":"roche-bcg-matrix","title":"Roche  Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eRoche’s BCG Matrix snapshot shows which franchises are fueling growth and which need tough choices—think oncology stars versus legacy products that may be slipping. Want a clear map of market share, growth trajectories, and cash flow realities? Purchase the full BCG Matrix for quadrant-by-quadrant analysis, data-backed moves, and ready-to-use Word and Excel files that let you act fast and present with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVabysmo (ophthalmology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2024 Vabysmo (faricimab) continues fast-growing adoption in retinal disease, grabbing share in an anti-VEGF market that is still expanding following its 2022 approval and Q16W dosing label flexibility.\u003c\/p\u003e\n\u003cp\u003eIts strong clinical profile and dosing flexibility are pulling demand across wet AMD and DMO, with real-world uptake accelerating as clinics adopt extended-interval regimens.\u003c\/p\u003e\n\u003cp\u003eKeep the foot on the gas: invest in access, supply capacity, and real-world evidence generation to cement leadership and, if momentum holds, mature into a durable cash engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTecentriq (immuno‑oncology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTecentriq (atezolizumab) holds leadership positions with approvals since 2016 in urothelial carcinoma and later expansions into NSCLC and triple‑negative breast cancer, yet label growth remains. The immuno‑oncology sector continues expansion and combination strategies (IMpower program) open new indications. Roche must sustain heavy clinical investment and targeted partnerships to defend share and scale the brand while demand is high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOcrevus (neuroscience, MS)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOcrevus, approved since 2017 and available in over 90 countries, has delivered category-defining outcomes in MS with uptake in \u0026gt;300,000 patients globally and 2023 sales near $6.0bn, underpinning a healthy market and ongoing switch dynamics. Roche should double down on patient support and geographic expansion to lock in share and invest in lifecycle extensions to extend the runway.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFoundation Medicine (CGP\/companion diagnostics)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFoundation Medicine, acquired by Roche for 2.4 billion USD in 2018, sits in the BCG Stars quadrant as CGP rides the still-growing precision‑oncology wave; its FDA‑approved FoundationOne CDx underpins strong pharma partnerships and payer engagement, reinforcing a durable moat and volume growth. Invest in assay breadth, faster turnaround, and expanding global reimbursement to sustain scale, which amplifies Roche’s oncology ecosystem.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTag: FDA‑approved companion diagnostic\u003c\/li\u003e\n\u003cli\u003eTag: Roche ownership 2018, 2.4B USD\u003c\/li\u003e\n\u003cli\u003eTag: Priorities — assay breadth, TAT, reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore Lab Diagnostics (cobas systems)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCore Lab Diagnostics (cobas systems) remain a Star for Roche as high-throughput platforms show steady test‑menu expansion and new installs in 2024, with clinical volumes rebounding and reagent pull‑through accelerating year‑over‑year. Prioritizing service, uptime and menu leadership is critical to sustain placements and outpace rivals; today the portfolio is positioned to transition to a long‑term cash cow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003e2024: cobas drives majority of core lab reagent volumes amid rising placements\u003c\/li\u003e\n\u003cli\u003eFocus: service uptime and menu breadth to maximize reagent pull‑through\u003c\/li\u003e\n\u003cli\u003eOutlook: near‑term Star, likely cash‑cow transition as scale and recurring reagents stabilize\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQ16W dosing fuels fast 2024 uptake; MS therapy \u003cstrong\u003e\u0026gt;300,000\u003c\/strong\u003e pts, \u003cstrong\u003e~$6.0bn\u003c\/strong\u003e sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVabysmo (faricimab) drives fast 2024 uptake in wet AMD and DMO with Q16W dosing flexibility and expanding clinic adoption.\u003c\/p\u003e\n\u003cp\u003eOcrevus remains category‑defining with \u0026gt;300,000 patients treated and ~$6.0bn sales in 2023, supporting continued MS market leadership.\u003c\/p\u003e\n\u003cp\u003eFoundation Medicine (Roche 2018, $2.4bn) anchors CGP with FDA‑approved FoundationOne CDx and growing pharma partnerships.\u003c\/p\u003e\n\u003cp\u003ecobas core lab platforms show rising installs and reagent pull‑through in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2023\/24 KPI\u003c\/th\u003e\n\u003cth\u003ePriority\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVabysmo\u003c\/td\u003e\n\u003ctd\u003eQ16W uptake 2024\u003c\/td\u003e\n\u003ctd\u003eAccess \u0026amp; RWE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOcrevus\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;300k pts; ~$6.0bn sales (2023)\u003c\/td\u003e\n\u003ctd\u003eSupport \u0026amp; lifecycle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFoundation Med\u003c\/td\u003e\n\u003ctd\u003eAcq $2.4bn (2018)\u003c\/td\u003e\n\u003ctd\u003eAssay \u0026amp; reimbursement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ecobas\u003c\/td\u003e\n\u003ctd\u003e2024 rising installs\u003c\/td\u003e\n\u003ctd\u003eService \u0026amp; menu\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG analysis of Roche's portfolio: Stars, Cash Cows, Question Marks and Dogs with clear invest, hold or divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Roche BCG Matrix mapping each unit to a quadrant — clears portfolio clutter and speeds C‑suite decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHerceptin\/Perjeta franchise (oncology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHerceptin\/Perjeta remains a cash cow for Roche with a massive installed base and strong clinician familiarity, though global HER2 market growth has plateaued and biosimilar uptake has eroded originator volumes in many markets. The franchise continues to generate meaningful free cash flow, supporting R\u0026amp;D and next-gen assets. Focus on pricing optimization, defending high-value segments (adjuvant\/metastatic combinations) and portfolio mix management. Milk efficiently and reallocate surplus into next-generation oncology pipelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMabThera\/Rituxan (immunology\/oncology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMabThera\/Rituxan remains a large, mature Roche franchise with stable but slow volume growth; 2023 sales were roughly USD 3.5 billion as biosimilar uptake dampened expansion. Profitability stays solid despite mounting competitive pressure, with gross-margin resilience supporting cash generation. Management emphasizes cost discipline, tighter channel execution and selective tender wins, recycling cash to fund higher-upside pipeline bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTissue Diagnostics (Ventana)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTissue Diagnostics (Ventana) is embedded in pathology workflows with sticky instruments and consumables, driving high recurring revenue; Roche Diagnostics reported mid-single-digit sales growth in 2024. Volumes are mature and predictable with attractive margins; incremental menu additions and automation (including digital pathology integrations) improve throughput. Maintain service excellence and harvest cash from the installed base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiabetes Care (Accu‑Chek)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDiabetes Care (Accu‑Chek) is a broad-footprint cash cow for Roche in 2024, delivering steady, predictable cash flows while category growth remains modest and fiercely competitive; margins benefit from scale and strong brand trust. Keep operations lean, defend retail\/clinic channels, streamline SKUs, and redirect cash to higher-growth platforms.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScale-driven margins\u003c\/li\u003e\n\u003cli\u003eModest market growth\u003c\/li\u003e\n\u003cli\u003eProtect core channels\u003c\/li\u003e\n\u003cli\u003eSKU rationalization\u003c\/li\u003e\n\u003cli\u003eFund growth bets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized PCR menus (non‑COVID)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCentralized PCR menus (non‑COVID) represent established test panels with steady lab demand; growth in 2024 was incremental rather than explosive, driven by routine infectious disease and oncology workflows. Reagent pull‑through is sustained via Roche installed base and contracting; operational focus should be productivity, uptime and cash generation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstalled base: core revenue engine\u003c\/li\u003e\n\u003cli\u003e2024: steady pull‑through, mid‑single‑digit volume growth\u003c\/li\u003e\n\u003cli\u003ePriority: maximize uptime, optimize contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDefend pricing, cut SKUs, reinvest cash - steady growth in oncology and diagnostics.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHerceptin\/Perjeta: large cash generator despite HER2 market plateau and biosimilar erosion; continue pricing focus and reinvestment. MabThera\/Rituxan: mature franchise with solid margins; biosimilars trimmed volumes (2023 sales ~USD 3.5bn). Ventana diagnostics and centralized PCR: mid-single-digit growth in 2024 with high recurring consumables pull‑through. Accu‑Chek: steady cash flow, defend channels and streamline SKUs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 signal\u003c\/th\u003e\n\u003cth\u003ePriority\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHerceptin\/Perjeta\u003c\/td\u003e\n\u003ctd\u003ePlateau\/biosimilars\u003c\/td\u003e\n\u003ctd\u003ePrice\/defend segments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMabThera\/Rituxan\u003c\/td\u003e\n\u003ctd\u003eStable margins\u003c\/td\u003e\n\u003ctd\u003eCost discipline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVentana\/PCR\u003c\/td\u003e\n\u003ctd\u003eMid-single-digit growth\u003c\/td\u003e\n\u003ctd\u003eUptime\/contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccu‑Chek\u003c\/td\u003e\n\u003ctd\u003eSteady cash\u003c\/td\u003e\n\u003ctd\u003eSKU\/retain channels\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eRoche  BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Roche BCG Matrix file you’re previewing is the exact document you’ll receive after purchase. No watermarks, no demo text—just a fully formatted, analysis-ready report tailored for strategic clarity. Once bought, the full file is immediately downloadable and editable for presentations or planning. Designed by strategy experts, it’s ready to use with no surprises or revisions needed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674578960761,"sku":"roche-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/roche-bcg-matrix.png?v=1755791933","url":"https:\/\/portersfiveforce.com\/products\/roche-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}